ライフサイエンスコーパス: active hepatitis

1 at have previously been described as chronic active hepatitis.

2 from HBV-positive liver samples with chronic active hepatitis.

3 n's syndrome, primary biliary cirrhosis, and active hepatitis.

4 pathology review shows 28 (80%) have chronic active hepatitis, 25 (71%) have fibrosis, and 3 (9%) hav

5 , which confirmed their impact on the immune active hepatitis after HBeAg seroconversion.

6 elical microorganism associated with chronic active hepatitis and a high incidence of hepatocellular

7 st observation of H. cinaedi associated with active hepatitis and colitis in a nonhuman primate.

8 icus infection develop a progressive chronic active hepatitis and liver tumors, despite the presence

9 gs suggest that helicobacter-induced chronic active hepatitis arises through the process of lymphoid

10 Patients with known CNS lymphoma, active hepatitis B or C infection, or HIV were excluded.

11 I or IV heart failure; uncontrolled, HIV, or active hepatitis B or C infection; or active haemolytic

12 er year) should prompt treatment initiation, active hepatitis B or C virus coinfection, cardiovascula

13 Potential kidney donors with active hepatitis B virus (HBV: positive hepatitis B surf

14 ) therapy remains a mainstay of treatment in active hepatitis B.

15 l-mediated diseases such as AIDS and chronic active hepatitis between humans and chimpanzees.

16 We show that blood from patients with active hepatitis C (alanine aminotransferase [ALT] level

17 However, from a public health perspective, active hepatitis C and B continue to drive most of the g

18 of thirty-six plasma and serum samples from active hepatitis C cases, and healthy individuals, with

19 f therapy, one because of the development of active hepatitis C following cycle 1, and one because of

20 der age (P < .001), HIV infection (P = .04), active hepatitis C virus (HCV) infection (P = .02), and

21 The early diagnosis of active hepatitis C virus (HCV) infection remains a signi

22 The role of active hepatitis C virus (HCV) replication in chronic ki

23 .21), injection drug use (4.89; 1.95-12.26), active hepatitis C virus infection (3.39; 1.10-12.26), a

24 BC and 35 disease controls including chronic active hepatitis C, extrahepatic biliary obstruction (EB

25 e anti-HCV positive and only one patient had active hepatitis C.

26 gnosis declined over time and was highest in active-hepatitis C (HCV) (32.7 vs cured-HCV 8.3, ALD 9.0

27 s infection in A/JCr mice results in chronic active hepatitis characterized by perivascular, periport

28 ronic infection that can progress to chronic active hepatitis, cirrhosis, and primary hepatocellular

29 tocarcinogenesis can occur in the absence of active hepatitis, correlating with high HBV surface anti

30 recognized bacterium associated with chronic active hepatitis, hepatic carcinoma, and inflammatory bo

31 Liver biopsies indicated mild-to-moderate active hepatitis in 6 children, some with and some witho

32 This is the first observation of H. canis in active hepatitis in a dog and correlates with recent fin

33 n with Helicobacter hepaticus causes chronic active hepatitis in certain strains of mice and is assoc

34 or histologic findings at presentation (mild active hepatitis, moderately active hepatitis, or cirrho

35 sentation (mild active hepatitis, moderately active hepatitis, or cirrhosis).

36 d in liver samples from HBV-infected chronic active hepatitis patients when compared with normal live

37 H. hepaticus causes chronic active hepatitis, with progression to hepatocellular tum